ライフサイエンスコーパス: antibody titer

1 nt was seroconversion or a >/=4-fold rise in antibody titer.

2 resistance were responsible for the reduced antibody titer.

3 was positively associated with neutralizing antibody titers.

4 horses developed reversible anti-eIL-5 auto-antibody titers.

5 from all symptomatic dengue disease at high antibody titers.

6 pite the presence of high serum neutralizing antibody titers.

7 achieved despite the lack of appreciable Env antibody titers.

8 thin a narrow range of preexisting anti-DENV antibody titers.

9 pecific CD4(+) T-cell responses, and low Env antibody titers.

10 assay was used to measure patient and donor antibody titers.

11 number of oocysts in control mosquitoes) and antibody titers.

12 rospectively by unusually high ZIKV-specific antibody titers.

13 jects developed protective anti-rabies virus antibody titers.

14 s demonstrated by similar serum neutralizing antibody titers.

15 going lowering of Ig levels and CMV-specific antibody titers.

16 of stool samples or 4-fold increase in serum antibody titers.

17 efficacy correlated with serum neutralizing antibody titers.

18 polymerase chain reaction and serum-specific antibody titers.

19 memory B-cell function and influenza A(H1N1) antibody titers.

20 ent but does not always result in protective antibody titers.

21 sure histamine release (HR) and specific IgE antibody titers.

22 ters and lowest among those with the highest antibody titers.

23 Memory probe vaccination increased all antibody titers.

24 aled a correlation of immunogen density with antibody titers.

25 mean serum RSV plaque-reduction neutralizing antibody titer, 1:64).

26 ly immunogenic array and induce neutralizing antibody titers 10-fold higher than the prefusion-stabil

27 cted in 2015 showed a high prevalence of IDV antibody titers (11.7%), while archive sera from 2009 sh

28 the cell-grown influenza A/Washington virus antibody titer (3C.2a2) was protective (60% reduction; P

29 We measured antibody titers (50% plaque reduction neutralization tes

30 esponse was impaired in 87% of patients (ie, antibody titer above cutoff and twofold increase between

31 This occurred despite neutralizing-antibody titers above the minimum levels required for pr

32 ents had a >=4-fold increase in neutralizing antibody titer after 3 doses of vaccine, whereas none of

33 >=4-fold rise in hemagglutination inhibition antibody titer after challenge.

34 While anti-Abeta antibody titers after AV-1953R immunization were similar

35 Despite a slight waning in antibody titers after primary challenge, enhanced antibo

36 >=4-fold increases in serum RSV-neutralizing antibody titers after the RSV season without RSV-MAARI.

37 was detected using ELISA assay, neutralizing antibodies titers against coxsackievirus A16 (CA16), ent

38 fitness advantage by measuring neutralizing antibody titer against reporter virus particles (RVPs) r

39 e antigen, most of them also had lower or no antibody titer against the challenge antigen.

40 ed sera demonstrated a >/=4-fold increase in antibody titer against the infecting type.

41 ccine candidate provided strong neutralizing antibody titers against all four viruses.

42 When stratified based on t1/2, the antibody titers against circumsporozoite protein and mer

43 We observed increased neutralizing antibody titers against DENV2 in ZIKV-infected individua

44 n based on serum hemagglutination inhibition antibody titers against each vaccine strain.

45 d vaccines generated significant circulating antibody titers against Env after a single i.m. immuniza

46 amily income group had the highest levels of antibody titers against hepatitis B vaccine.

47 beads, and antibody breadth and neutralizing antibody titers against homologous and heterologous tier

48 associated with infection, when adjusted for antibody titers against influenza A/Washington virus (15

49 Similarly, antibody titers against influenza virus hemagglutinin an

50 Natural antibody titers against M2FA are elevated in atheroscler

51 mmunogen is able to elicit high neutralizing antibody titers against MERS-CoV.

52 Infant antibody titers against RSV-A were 3X higher compared to

53 ial demonstrated persistence of neutralizing antibody titers against TAK-003 over three years in chil

54 for antipneumococcal immunoglobulin G (IgG) antibody titers against the 7 serotypes shared by PCV7,

55 Individuals vaccinated in 2017-2018 had high antibody titers against the egg-adapted vaccine strain a

56 for antipneumococcal immunoglobulin G (IgG) antibody titers against the seven serotypes shared by PC

57 We assessed neutralizing antibody titers against yellow fever virus in blood samp

58 s in all regimens significantly boosted EnvA antibody titers, although vaccine order in the heterolog

59 nistration during pregnancy did not decrease antibody titers among infants at birth.

60 ulted in a decrease in average measles virus antibody titers among plasma donors, which is reflected

61 ie, a >/=4-fold increase in the neutralizing antibody titer and a titer of >/=40 from month 13 to mon

62 RTS,S-induced NPNA-specific antibody titer and avidity have been associated with hig

63 The antibody titer and avidity of immunoglobulin (Ig) G spec

64 major inhibitory effect on parasite-specific antibody titers and a failure to control parasite replic

65 e infected with CX4C viruses also had higher antibody titers and a Th1-biased T cell memory response

66 hedule, and there may be an early benefit in antibody titers and activated CD8+ T cells by the admini

67 The vaccine elicited high virus neutralizing antibody titers and conferred complete protection in all

68 Serial serum anti-alpha-toxin antibody titers and functional alpha-toxin neutralizatio

69 d in seasonal influenza vaccines to increase antibody titers and improve neutralizing activity, trans

70 gative results correlated with lower surface antibody titers and longer time since infusion, suggesti

71 ed cells, and were associated with decreased antibody titers and lower numbers of plasma cells.

72 tients with low to intermediate preinfection antibody titers and lowest among those with the highest

73 and i.m. routes prompted high levels of HI antibody titers and MN against A/H1N1 and A/H3N2 influen

74 While antibody titers and neutralization are considered the go

75 mice showed that Fc-d E1E2 elicited anti-E2 antibody titers and neutralization of HCV pseudotype vir

76 Antibody titers and PCA concentrations at day 30 were si

77 nfluenza infection, contribute to protective antibody titers and persist mainly in the spleen with re

78 lysaccharide adjuvants enhances neutralizing-antibody titers and protection against clinical disease

79 t significantly increased serum neutralizing-antibody titers and reduced lung virus titers on day 3 p

80 AP) induced both strong anti-alpha-synuclein antibody titers and regulatory T cells (Tregs).

81 objective was to assess the antipneumococcal antibody titers and seroprotection rates of allogeneic H

82 f a CRM197-MenC vaccine increasing anti-MenC antibody titers and serum bactericidal activity (SBA) ag

83 ciation between preexisting variant-specific antibody titers and subsequent carriage of pneumococcus

84 y of the offspring, measured by neutralizing antibody titers and survival rates after virus challenge

85 The HRV dose increases antirotavirus serum antibody titers and the proportion of infants with detec

86 ant virus particles elicited protective RABV antibody titers, and animals immunized with a combinatio

87 creting cells and memory B cells, higher IgG antibody titers, and better persistence of antibody tite

88 (anti-PT) or anti-filamentous hemagglutinin antibody titers, and by genetic testing (polymerase chai

89 owever, CTD2 induced strong Bmem cell-driven antibody titers, and the CTD2 antibody was neutralizing

90 nstrated that CTD1 induced strong recall IgG antibody titers, and this led to the development of func

91 like particles resulted in high neutralizing antibody titers ( approximately 1/100,000) that protecte

92 ond vaccination significantly increased EnvA antibody titers (approximately 20-fold from the median e

93 Pertussis antibody titers are higher in acellular pertussis (aP)-

94 (gH pentamer), (iv) equivalent neutralizing antibody titers are induced in mice following immunizati

95 Since high antibody titers are required for AD vaccine efficacy, we

96 t in a major portion of the population these antibody titers are suboptimal and IVIG therapy only inc

97 We evaluated cPRA reduction, calculated per antibody titer, as a desensitization trial endpoint.

98 Geometric mean neutralizing antibody titers, as measured by the 50% plaque reduction

99 lso demonstrate that anti-spike neutralizing antibody titers, as well as Fc-mediated functional antib

100 -deglycosylated hemocyanins elicited reduced antibody titers, as well as partially diminished antitum

101 ginine and citrulline levels, anti-ADI-PEG20 antibody titer, ASS1 methylation status, and metabolic r

102 tested (91.1%) were seropositive; antiviral antibody titers assayed by two pan-Ig assays increased d

103 gue questionnaire scores, and serum anti-TPO antibody titers at 6, 12, and 18 months.

104 ID rabies vaccination induces acceptable antibody titers at a fraction of the dose.

105 28 days after dose 1 significantly increased antibody titers at day 56, but the effect was diminished

106 ogenicity based on hepatitis B surface (HBs) antibody titers at Days 1, 28, 90, 180 and 210, adverse

107 titers but significantly higher neutralizing antibody titers at higher doses.

108 lar immune responses, including neutralizing antibody titers at levels comparable to those found in c

109 ion in transplant recipients, we measured HI antibody titers at presentation and 4 weeks later.

110 (minimum titer of 1:40 and >/=4-fold rise in antibody titer) at 1 month postvaccination based on seru

111 interventional trial measuring NAb and total antibody titers before and after CP transfusion over a 1

112 Despite similar neutralizing antibody titers between HIV-infected and -uninfected wom

113 Similar neutralizing antibody titers, binding IgG titers measured against a b

114 AV IgG and IgA titers and virus-neutralizing antibody titers but not hemagglutinin stalk antibody tit

115 er immunizations can increase serum anti-Env antibody titers but only transiently.

116 ticipants, with similar glycoprotein-binding antibody titers but significantly higher neutralizing an

117 Despite the induction of robust neutralizing antibody titers by all vaccines, breakthrough seeding of

118 come was seroprotection rate (anti-influenza antibody titers by hemagglutination inhibition) 21 d aft

119 tionic NPs led to enhanced systemic and lung antibody titers compared with anionic NPs.

120 with a reduction in anti-P. gingivalis serum antibody titers compared with wild-type infected control

121 Typically such studies demonstrate improved antibody titer comparing monomeric and nano-arrayed anti

122 edictors of seroconversion (dichotomous) and antibody titer (continuous), respectively.

123 Anti-VZV plasma antibody titers correlated positively with the number of

124 Since antibody titers correlated with protection in preclinica

125 Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, sug

126 Antibody titers decrease with time following influenza v

127 Median serum anti-TPO antibody titers decreased from 2232 to 152 IU/mL, for a

128 cell recovery, transgene-specific serum IgG antibody titers develop and reach a concentration equiva

129 Passively acquired neutralizing antibody titers dropped below detection limits between 2

130 s JCPyV naive pretransplant, but showed high antibody titers during the neurological symptoms, with t

131 elease over 28 days resulted in neutralizing antibody titers equivalent to two bolus vaccinations adm

132 eolar bone loss and serum anti-P. gingivalis antibody titers equivalent to wild-type infected mice.

133 ixture distributions, we show that 2009 H1N1 antibody titers fall into four titer subgroups and that

134 covering from COVID-19 and demonstrated that antibody titers fall over 3-4 months.

135 g primary H1N1 virus infection but increased antibody titers following a sequential infection with ei

136 enhanced the magnitude and kinetics of serum antibody titers following vaccination, and induced a gre

137 not all recovered patients develop adequate antibody titers for donation and the relationship betwee

138 We assessed neutralizing antibody titers for the four dengue serotypes (DENV) up

139 r a 4-fold rise in virus-specific IgM or IgG antibody titers from acute- and convalescent-phase sera.

140 rates and lower hemagglutination-inhibition antibody titer geometric mean fold increase against infl

141 Geometric mean neutralizing antibody titers (GMTs) by plaque reduction neutralizatio

142 tage of those with rabies virus neutralizing antibodies titers >= 0.5 IU/mL on day 14.

143 seroprotection (hemagglutination-inhibition antibody titer >/=1:40 on day 28 after vaccination).

144 ects in both study groups possessed a rabies antibody titer >0.5 IU/mL on day 7 following the booster

145 1 (99.3%) in each study group, had a rabies antibody titer >0.5 IU/mL on day 7 following the booster

146 Immunogenicity was defined as an anti-drug antibody titer >=10 AU/mL using a drug-tolerant enzyme-l

147 cts, 43 (91.5%) subjects had JE neutralizing antibody titers >/=10 (reciprocal serum dilution) agains

148 High IgG avidity and neutralizing-antibody titers >40000 to measles (indicating reinfectio

149 th endocarditis had phase I immunoglobulin G antibody titers >800 but did not meet the CSTE case defi

150 Furthermore, compared with HIV-unexposed, antibody titers >=330 mIU/mL (ie, presumed serocorrelate

151 Preexisting Ad26- or Ad35-neutralizing antibody titers had no effect on vaccine safety and litt

152 iruses 1 to 4 (DENV1-4), a specific range of antibody titer has been shown to enhance viral replicati

153 tivity to avian influenza (AI) via low-level antibody titers has been reported in the general populat

154 hows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells t

155 uding higher polysaccharide-specific capsule antibody titers, higher interferon gamma and interleukin

156 The measles virus antibody titer, however, is a potency requirement for IV

157 xes not only induced multi-fold higher serum antibody titer in comparison to all other formulations i

158 ice did not generate a robust neutralization antibody titer in comparison to the HSV-1 0DeltaNLS-vacc

159 of protein boosted binding and neutralizing antibody titers in 100% of primed subjects following thi

160 performed cross-sectional analysis of serum antibody titers in 546 adult subjects stratified by age

161 Antibody titers in a subset of subjects were determined

162 vaccines could also boost RSV neutralization antibody titers in African green monkeys that had been i

163 give significant improvement of early IgG2a antibody titers in BALB/c mice following primary vaccina

164 urified recombinant SLTRiP protein gave high antibody titers in both inbred and outbred mice.

165 High ZIKV-specific antibody titers in cases were unrelated to prior dengue

166 oglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients.

167 nts with and without detectable anti-GM1 IgM antibody titers in enzyme-linked immunosorbent assay, bu

168 the ZEBOV-specific cTfh data correlated with antibody titers in human vaccines and unexpectedly with

169 We analyzed neutralizing antibody titers in individuals aged 1-88 who received th

170 To mitigate the decline in measles virus antibody titers in IVIGs and to ensure consistent produc

171 ultiple orders of magnitude higher levels of antibody titers in mice that neutralize pseudovirus cell

172 high and dose-dependent SARS-CoV-2 specific antibody titers in mouse sera, as well as robust neutral

173 mation (DS-Cav1 F) induces high neutralizing antibody titers in naive animals, but it remains unknown

174 h trends toward higher anti-circumsporozoite antibody titers in participants protected against infect

175 However, the value of anti-PLA2R1 antibody titers in predicting patient outcomes is unknow

176 Perreault and colleagues examined antibody titers in sequential samples from serum donors

177 tes, confirmed by high ZIKV immunoglobulin M antibody titers in serum and cerebrospinal fluid.

178 The antibody titers in the prechallenge sera were not predic

179 30-fold increases of RSV-neutralizing serum antibody titers in the presence and absence of added com

180 zing (VN) antibodies, as the heterologous VN antibody titers in the sera of G9P[13]-inoculated pigs w

181 The neutralizing antibody titers in the sera of the offspring of the dams

182 ldren with >=1 prior infection, intermediate antibody titers increase, whereas high titers lower, the

183 EBOV GP and RABV GP-specific antibody titers increased exponentially during the trial

184 l 24 (100%) individuals during CONV; binding antibody titers increased from AIM through CONV, reachin

185 in vivo, caused up to a 10(4)-fold boost in antibody titers, increased Th1-associated responses, and

186 combined with a potent adjuvant in boosting antibody titers induced by a preceding DNA/MVA immunizat

187 eatment year, most likely due to more stable antibody titers induced by a single booster injection.

188 However, the antibody titers induced by H7 viruses were significantly

189 These findings suggest that a single IgG antibody titer is an unreliable measure of diagnosis and

190 on of chi10069(pYA5199) induced strong serum antibody titers (log(10) mean value, 4.2), secretory IgA

191 0 participants who received the drug; 29 had antibody titers lower than 1:1000, of whom 12 had positi

192 uenza viruses, protection is correlated with antibody titers measured by hemagglutination inhibition

193 ion and analyzed in relation to preinfection antibody titer (measured by inhibition enzyme-linked imm

194 Varicella zoster virus (VZV) antibody titers (measured by a VZV glycoprotein-based en

195 Alum increased antibody titers; MF59(R) induced strong antibody and IL-

196 ble HAI-antibodies but high flu-specific IgG-antibody titers mounted rapid functional antibodies afte

197 diphtheria as defined by a protective serum antibody titer of >/=0.01 IU/mL.

198 on these participants had RSV-A neutralizing antibody titers of >/=1:512, and >70% had titers of 1:10

199 All subjects achieved accepted neutralizing antibody titers of >=0.5 IU/mL following the second rabi

200 Antibody titers often increased across pediatric groups

201 We showed the effect of preinfection antibody titer on disease severity was mediated by viral

202 Kinetics of antibody titers over time among study groups were examin

203 plenomegaly (P < .0001), and increased serum antibody titers (P < .01), whereas control mice did not.

204 ibition, neuraminidase inhibition, and stalk antibody titers; peripheral blood leukocyte host gene ex

205 ve of 19 vaccinees had >=4-fold increases in antibody titers postsurveillance without RSV-MAARI, indi

206 Re-emergence of or increase in antibody titers precedes a clinical relapse.

207 etected in PBMCs were highly correlated with antibody titers prechallenge and protection in the RRR c

208 Circumsporozoite protein (CSP)-specific antibody titers, prechallenge, were associated with prot

209 Further, although high preexisting anti-DENV antibody titers protected against DENV1, DENV3, and ZIKV

210 Serum bactericidal antibody titers (rabbit complement) were measured agains

211 ate and <2-fold difference in geometric mean antibody titer ratio.

212 Geometric mean antibody titer ratios (3D/2D) for HPV-16 and HPV-18 were

213 eorgia donors (n = 1493), 11.1% demonstrated antibody titers reactive with R. rickettsii at titers >=

214 RSV severity was correlated with antibody titers, reduced T and B cells, dysregulated inn

215 nts undergoing plasmapheresis/low-dose IVIg, antibody titer reduction correlated with number of treat

216 Antibody titers remained at similar levels from 1 to 2 y

217 directly compared and determine the minimal antibody titers required to halt transmission in differe

218 % of older children and adults had >/=4-fold antibody titer rise against influenza A(H3N2) and B anti

219 the serum RSV-plaque-reduction neutralizing antibody titer (RSV-PRNT).

220 Despite a decline in stalk-specific serum antibody titers, sequential sH1N1 influenza virus-infect

221 e association between preinfection anti-DENV antibody titer, serum viral load, and disease severity,

222 None of the crew members with neutralizing antibody titers showed evidence of bona fide viral infec

223 kers with negative SARS-CoV-2-specific serum antibody titers showed SARS-CoV-2-specific IgA in mucosa

224 Although neutralizing antibody titers showed that Sf9-derived sE2 induced mode

225 esence of SARS-CoV/SARS-CoV-2 cross-reactive antibody titers specific for the receptor-binding domain

226 ry cells is directly correlated with insulin antibody titers, suggesting insulin-specific T- and B-ce

227 Total SARS-CoV-2 antibody titers tended to be higher in the convalescent

228 Ad26-Ad35 elicited significantly higher EnvA antibody titers than Ad35-Ad26.

229 ith higher hemagglutination inhibition (HAI) antibody titers than antisera elicited by VLP vaccines w

230 ose induced higher binding- and neutralizing-antibody titers than the 25-mug dose, which supports the

231 sition elicited higher GP neutralizing serum antibody titers than the N-P viruses, and unmodified GP

232 Ps induced significantly higher neutralizing antibody titers than the post-F/F-containing VLPs or the

233 enter B cell responses that generated higher antibody titers than the soluble trimers and liposome-be

234 owed that VLPs generated higher neutralizing antibody titers than those with the DNA vaccines, with C

235 F mutant did not induce higher neutralizing antibody titers than wild-type F.

236 ecombinant E1E2 vaccine antigen induces high-antibody titers that are insufficient to neutralize dive

237 f mice with VSV-eGFP-SARS-CoV-2 elicits high antibody titers that neutralize SARS-CoV-2 and target th

238 nt formulation will be required to establish antibody titers that persist for several malaria transmi

239 d (primed) with RSV resulted in total anti-F antibody titers that were 10- to 12-fold higher than tit

240 cond trial of subjects with low pre-existing antibody titers, there was significant impairment in H1N

241 undetectable viremia, and high neutralizing antibody titers throughout the disease course.

242 53%) paired sera had a >/=4-fold increase in antibody titer to cluster-related strains as well.

243 Postvaccination neutralizing antibody titers to 3c2.A and 3c2.A2 were higher in Flubl

244 Post-vaccination neutralizing antibody titers to 3c2.A and 3c2.A2 were higher in Flubl

245 Here, we show that antibody titers to a key target, the repeat region of th

246 A population's natural distribution of antibody titers to an endemic infectious disease may inc

247 V shedding and potential utility of maternal antibody titers to corroborate congenital ZIKV infection

248 Preexisting high antibody titers to dengue virus were associated with red

249 These data suggest that high neutralizing antibody titers to DENV and to ZIKV are associated with

250 Post-vaccination neutralizing antibody titers to H1N1 were similar among the different

251 Postvaccination neutralizing antibody titers to H1N1 were similar among the different

252 Antibody titers to H1N1pdm09 persisted above the protect

253 uarter of the United States was surveyed for antibody titers to hepatitis A virus (HAV), measles viru

254 The objectives are to compare antibody titers to HPV 6, 11, 16, and 18 and rate of abn

255 Antibody titers to HPV4 were lower for all serotypes in

256 13 of clinical illness, a marked increase in antibody titers to most EBOV proteins and affinity matur

257 We describe the distributions of antibody titers to subtypes 2009 H1N1 and H3N2.

258 n in children but not adults correlates with antibody titers to the hemagglutinin surface protein.

259 d between 2009 and 2013 from which we report antibody titers to the influenza virus HA1 protein using

260 ecific antibodies, and individuals with high antibody titers to this protein have a lower rate of rei

261 Serum antibody titers to vaccine-related antigens were measure

262 Following vaccine-mediated boosting of antibody titers to viral interleukin-10, there was modes

263 e association between preinfection anti-DENV antibody titers, viral load, and disease severity among

264 High level of stalk antibody titers was associated with the selection of the

265 No elevation of anti-PT antibody titers was observed in the patient.

266 Mean antibody titers were 3.6 and 0.35 IU/mL against tetanus

267 Neutralizing measles virus antibody titers were above the threshold for protective

268 events after column reuse, and anti-A/anti-B antibody titers were assessed.

269 anti-PT IgG, anti-Prn IgG, and anti-FHA IgG antibody titers were comparable for both groups.

270 obulin G concentrations and opsonophagocytic antibody titers were demonstrated 1 month after each of

271 Significantly lower antibody titers were detected in HIV-infected mothers an

272 tion-inhibition and neuraminidase-inhibition antibody titers were determined in subjects >/=13 years.

273 tion-inhibition and neuraminidase-inhibition antibody titers were determined to assess susceptibility

274 Robust neutralizing antibody titers were elicited and maintained through 12

275 Although cytomegalovirus (CMV) antibody titers were higher in cases, CMV-specific T-cel

276 antibody titers but not hemagglutinin stalk antibody titers were lower in progestin-treated mice tha

277 Measles antibody titers were measured by enzyme-linked immunosor

278 -cell proliferation, cytokine secretion, and antibody titers were measured by using standard techniqu

279 after the booster dose, significantly lower antibody titers were measured in the Tdap group for anti

280 3 doses, and controls), rabies neutralizing antibody titers were measured to 1 year postvaccination.

281 (MAARI) and pre- and postsurveillance serum antibody titers were monitored.

282 Preexisting anti-NA antibody titers were most predictive of reduced influenz

283 Anti-CCHFV-GP IgG and neutralizing antibody titers were observed in surviving animals.

284 Highest antibody titers were observed in the 7.5 microg + 0.25 m

285 Serum anti-vaccine antibody titers were quantified by enzyme-linked immunos

286 261/surf or SL3261/sec, peak total serum IgG antibody titers were reached more rapidly in mice that r

287 hole-cell inclusion immunofluorescence serum antibody titers were recorded among infertile women seen

288 ZIKV-specific antibody titers were significantly higher in cases than

289 Average postvaccination antibody titers were similar across successive vaccinati

290 Initial alpha-toxin-specific antibody titers were similar, compared with those in the

291 Low (<1:64) neutralizing antibody titers were similarly detected in CMV-infected

292 Glycoprotein-binding antibody titers were sustained through 180 days in all p

293 s elicited high, saturating antigen-specific antibody titers when administered to mice in quantities

294 izing immunity with a saturated neutralizing antibody titer, which no longer increased after challeng

295 ombination showed increased antigen-specific antibody titer with an overall balanced Th1/Th2 response

296 ce of highly elevated serum immunoglobulin G antibody titers with a high avidity index (>/= 55%), abs

297 G antibody titers, and better persistence of antibody titers with MVA-B13R/SHIV than with MVA/SHIV.

298 may be at least partly related to measuring antibody titers with the traditional HI and MN assays, w

299 cats had measurable SARS-CoV-2 neutralizing antibody titers, with dogs from COVID-19 positive househ

300 h Pfs47 monomer induced significantly higher antibody titers, with higher binding affinity to Pfs47,